The current financial score of Sanara Medtech Inc is 7.20. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 28.14M, representing a year-over-year increase of 8.93%, while its net profit experienced a year-over-year increase of 77.52%.
The current valuation score of Sanara Medtech Inc is 8.76. Its current P/E ratio is -9.02, which is -58.41% below the recent high of -3.75 and -840.02% above the recent low of -84.78.
The current earnings forecast score of Sanara Medtech Inc is 6.00. The average price target is 35.00, with a high of 35.00 and a low of 35.00.
The current price momentum score of Sanara Medtech Inc is 1.56. Currently, the stock price is trading between the resistance level at 35.47 and the support level at 34.59, making it suitable for range-bound swing trading.
The current institutional shareholding score of Sanara Medtech Inc is 3.00. The latest institutional shareholding proportion is 15.50%, representing a quarter-over-quarter increase of 18.63%. The largest institutional shareholder is James Simons, holding a total of 67.40K shares, representing 0.00% of shares outstanding, with 36.56% increase in holdings.
The current risk assessment score of Sanara Medtech Inc is 6.36. The company's beta value is 1.22. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.